Staidson (Beijing) Biopharmaceuticals Co., Ltd.

The company was founded in August 2002 and listed on the Shenzhen Stock Exchange GEM on April 15, 2011. The company's main business is R&D, production and marketing of innovative drugs, especially biopharmaceuticals, with independent intellectual property rights. The company's main products are the innovative biological drug threeptiscene (mouse nerve growth factor for injection) and the specialty product sultaiqing (compound polyethylene glycol electrolyte powder (IV)). The company received honors such as the Beijing Economic and Technological Development Zone's top 50 tax payment growth enterprises in 2011, high-tech enterprises in Beijing, innovative pilot enterprises in the Zhongguancun National Independent Innovation Demonstration Zone, and the third prize of the Beijing Science and Technology Progress Award.